Danaher Corporation · NYSE:DHR
Danaher — J.P. Morgan Healthcare Conference 2015
16 slides from Danaher's conference presentation, Jan 13, 2015
Slide 1: J.P. Morgan Healthcare Conference
Exhibit 99.1 J.P. MORGAN HEALTHCARE CONFERENCE January 13, 2015
Slide 2: Forward Looking Statements
Forward Looking Statements Statements in this presentation that are not strictly historical, including any statements regarding events or developments that we believe or anticipate will or may occur in the future, are "forward-looking" statements within the meaning of the federal securities laws. Th
Slide 3: Strategic Platforms
Strategic Platforms Test & Life Sciences Industrial Environmental Dental Measurement & Diagnostics Technologies Water Quality Communications* Dental** Diagnostics*** Product ID $2.0B $1.0B $2.9B $4.8B $1.6B Gilbarco Veeder- Instruments Life Sciences Automation Root $2.0B $2.5B $0.8B $1.6B Figures re
Slide 4: Danaher Business System
PLP Danaher Business System DANAHER INNOVATION DEFINES OUR FUTURE THE BEST TEAM WINS DANAHER KAIZEN IS OUR WAY OF LIFE CUSTOMERS CUSTOMERS TALK, WE LISTEN WE COMPETE FOR SHAREHOLDERS
Slide 5: Current Update
Current Update Q4 played out largely as expected U.S. solid; Europe stable; High growth markets (HGM) lead but mixed performance 23 rd consecutive year of FCF>NI Optimizing our portfolio to improve and sustain our market leading positions ~$4.0B of acquisitions announced or closed in 2014 Pending RM
Slide 6: Life Sciences & Diagnostics
Life Sciences & Diagnostics Life Sciences Tools Diagnostics ~$15B ~$25B Market Size Market Size ~$2.5B ~$4.8B* 2014E Revenue 2014E Adjusted Revenue 65% Instruments 20% Instruments 35% Consumables/Service 80% Consumables/Service *Represents 2014E adjusted revenue; ~$0.2B of 2014E revenue from Devicor
Slide 7: Diagnostics Overview
Diagnostics Overview 2014E Financials Market Details Adjusted Revenue ~$4.8B* Market Size ~$25B Growth Rate +MSD Revenue Breakdown Growth Drivers Geographic Mix Healthcare expenditures increasing in HGMs Greater investment in preventative and predictive 6% medicine 20% Skilled labor shortage & cost
Slide 8: Building the Diagnostics Platform
Building the Diagnostics Platform 2004 2006 2008 2010 2012 2014 Radiometer Blood Gas Immunoassay Hemoglobin Leica Biosystems Histology Adv. Staining Histology Consumables Digital Pathology ISH/FISH Biopsy Beckman Dx * Core Lab Urinalysis Middleware Microbiology 2004 2014E *Pending, subject to custom
Slide 9: What You Will Hear Today
What You Will Hear Today Accelerating growth through organic investments in new products and feet-on-the street DBS improving customer satisfaction and operational performance while funding growth Acquisitions expanding addressable market and breadth of product offerings Driving +MSD core growth wit
Slide 10: Growth Investments – LS&D
Growth Investments – LS&D Increasing product launch cadence at Beckman Dx Automation solutions: Connectivity for DxH800 and FDA clearance for PowerExpress solutions Menu expansion: Vitamin D* and Automated AMH* (fertility) Enter Molecular Dx with Veris*; high volume fully automated PCR solution, ver
Slide 11: Investing for Growth – Beckman
Investing for Growth – Beckman Remediated quality management # of reagent SKUs on stock-out system Reduced FDA 510(k) clearance of Troponin Assay >75% Formal closure of all FDA warning letters Increased instrument reliability >50% Key Performance Improved to #1 (from #4) for service Indicator 2012 2
Slide 12: Iris Acquisition
Iris Acquisition Expanded offering for core hospital lab Revenue Op Profit Leader in automated urinalysis testing >10% growth ~2X Beckman’s first bolt-on acquisition Attractive market and business model ~$400M market growing +MSD/HSD ~70% consumables/~30% equipment Beckman’s scale accelerating growt
Slide 13: Devicor Acquisition
Devicor Acquisition Positions LBS at the front-end of breast cancer workflow A leader in vacuum-assisted breast biopsy $400M market segment growing +MSD Opportunity for integrated workflow from biopsy to diagnosis Control sample handling/processing to improve diagnostic quality Runway to expand into
Slide 14: Complementary Workflow
Complementary Workflow Customer value proposition Increased sample integrity and tissue quality Time reduction to accession and to processing of biopsies Automated data tracking from biopsy to path lab => reduced risk of sample mislabeling MammoPort with Revolve tray (under development) Leica Tissue
Slide 15: Summary
Summary Accelerating growth through organic investments in new products and feet-on-the street DBS improving customer satisfaction and operational performance while funding growth Acquisitions expanding addressable market and breadth of product offerings Driving +MSD core growth with significant run
Slide 16: Danaher
ay, DANAHER